Abbott Laboratories
ABT · NYSE
ABT · NYSE
Abbott is a global healthcare company whose business spans medical technology, diagnostics and nutrition. It earns revenue by selling healthcare products, including its Oncodetect molecular residual disease test, which is designed to detect traces of cancer during and after treatment. Its customer base includes healthcare providers and patients, as well as consumers of nutrition products. Abbott reported FY2025 revenue of $44.3 billion and net income of $6.5 billion, compared with revenue of $42.0 billion and net income of $13.4 billion in FY2024. The supplied evidence does not break out revenue or earnings contributions by business line.
Abbott rose 2.01% over the reported week, from $102.51 to $104.57. It reached a $104.88 close on Monday, then retreated to $103.10 on Tuesday and $102.64 on Wednesday before recovering to $104.57 on Thursday. Abbott announced Monday that its next-generation Oncodetect cancer residual disease test was commercially available, but the supplied evidence does not establish that the launch drove the initial advance. The company-specific backdrop was mixed: The Motley Fool cited nutrition as a drag on third-quarter sales growth, while Argus’s downgrade cited a cut to full-year 2026 sales-growth guidance. The evidence does not tie either development to particular daily moves, and no broad-market comparison is supplied to explain the weekly gain.
Abbott gained 2.20%, rising from $101.82 on Oct. 12 to $104.06 on Oct. 19. Shares advanced through the week, reaching $104.68 on Oct. 15 and a high close of $104.89 on Oct. 16, before retreating $0.83, or about 0.8%, on Oct. 19. The supplied evidence does not identify an operating announcement that explains the advance. JPMorgan, RBC Capital and Citigroup lowered their price targets on Oct. 16 while maintaining their ratings, but the shares still edged higher that day. The Q3 earnings and nutrition-separation headlines in the evidence do not establish a cause for trading through Oct. 19. No broad-market comparator was supplied, so the contribution of market conditions cannot be assessed.
Abbott shares rose 1.72%, from $100.10 on October 5 to $101.82 on October 12, after a sharp early-week drop and a strong final-session rebound. The stock fell 1.94% on October 6 to $98.16, then recovered unevenly to $99.60 by October 9 before gaining 2.23% on October 12. Zacks reported that Abbott gained as the broader market dipped on that final session, but the supplied evidence identifies no company-specific announcement that explains the full-week move. A TradingView article previewed Q3 earnings, and other headlines referenced heart-failure news, but the evidence does not connect either item to this week’s trading.
Abbott fell 2.76%, from $100.95 to $98.16, over the reported window. Shares first slid to $96.69 by Oct. 1, then recovered to $97.50 on Oct. 2. The clearest positive company-specific catalyst came Monday, Oct. 5, when the FDA approved new patient-facing features for Abbott’s CardioMEMS heart-failure system; shares rose to $100.10 that day. They reversed course on Oct. 6, falling 1.94% to $98.16 despite broader market gains, according to Zacks. That pullback erased most of Monday’s rebound and left the stock below its starting price. The supplied evidence does not identify a specific company catalyst for the earlier declines or the Oct. 6 reversal.
Abbott fell 4.33%, from $101.07 to $96.69, over the stated week. The decline was concentrated late in the trading sequence: shares slipped from $100.95 on September 29 to $98.83 on September 30, then fell again to $96.69 on October 1. Zacks reported the September 30 close was down 2.1% from the prior session and characterized Abbott’s dip as more significant than the broader market’s, but the supplied evidence identifies no company-specific event behind either decline. Abbott’s SimpleScreen CRC blood-test launch is reported in the evidence, but no date or trading-session connection is given. Rothschild & Co’s upgrade to Buy was dated October 2, after the last daily close supplied, so it does not explain the week’s selloff.
ABT rose 1.10% over the stated week, from $102.36 to $103.49. The supplied daily closes show a steady advance early in the trading period: the shares closed at $102.98 on September 21, climbed to $103.69 on September 22, then gave back $0.20 to finish at $103.49 on September 23. The available evidence does not identify company-specific news that drove this move. Headlines about Abbott’s Lingo partnership and competition in its segments provide no dated details establishing a weekly catalyst, and a director share transaction is not evidence of a trading driver. No market benchmark or broader-market news was supplied, so ABT’s relative performance cannot be assessed.
Abbott fell 4.39% over the period, from $110.36 to $105.52. Shares slipped on September 1, briefly recovered to $110.47 on September 2, then declined for two sessions before giving back another 2.59% on September 8, the largest daily loss and the week’s heaviest volume at 11.4 million shares. The company received FDA approval for its TactiFlex Duo cardiac-ablation catheter, a potentially supportive product catalyst, but the announcement did not prevent the selloff. Technical pressure was also evident as shares broke below the reported 200-day moving average of $106.31. The supplied evidence does not identify a fundamental negative surprise or broader-market driver explaining the full move.
ABT fell $2.80, or 2.51%, from $111.59 to $108.79 over the week. The stock opened the period at $110.36 after dropping from the prior $112.47 close, then extended its decline to $108.93 on Tuesday. It rebounded 1.41% to $110.47 on Wednesday, as noted by Zacks, but gave back that gain and more on Thursday, closing at $108.79. The supplied evidence does not identify a company-specific earnings release, guidance change, analyst action, or contract that explains the net decline. Abbott did announce a ready-to-feed Similac whole-milk formula launch, while reports of small insider disposals were tax- or award-related, but neither is linked to the trading. The week therefore appears to have moved without an identified company-specific catalyst.
Abbott shares fell $4.17, or 3.58%, over the week, from $116.64 to $112.47. The stock was essentially flat Monday at $116.67, slipped Tuesday, then lost 1.75% Wednesday and another 2.20% Thursday to close at $111.59 before rebounding 0.79% Friday. The available evidence does not identify a negative company-specific catalyst behind the two-day selloff. Instead, Zacks described Thursday’s decline as occurring while the broader market gained, suggesting company-specific underperformance without a stated trigger. Positive product developments, including FDA authorization for Abbott’s Libre Duo dual glucose-ketone sensor and CE Mark approval for the Amulet 360 heart device, did not prevent the decline. Friday’s recovery gave back only part of the Wednesday-Thursday drop.
Abbott Laboratories rose $1.50, or 1.40%, from $107.12 to $108.62 over the week. Trading was uneven: the stock fell $1.66 on August 4 after starting at $107.12, then stabilized on August 5 and rallied $2.25 on August 6 to $107.96. It gave back $0.15 on August 7 before adding $0.81 on August 10 to finish at the weekly high. The clearest company-specific catalyst was Wolfe Research upgrading Abbott to Outperform, an action reported by GuruFocus and MarketBeat. Articles also highlighted Abbott’s Established Pharmaceuticals growth and its Google health and glucose research partnerships, supporting sentiment, although the evidence does not establish their precise trading impact. No broader market driver is supplied.
Abbott shares fell 1.69% over the week, from $107.27 to $105.46. Trading was choppy: the stock rose to $108.00 on July 29, then dropped to $105.61 on July 30, was little changed July 31, rebounded to $107.12 on August 3, and gave back that recovery with a 1.55% decline on August 4. The supplied evidence contains no Abbott-specific announcement, earnings update, analyst action, or guidance change explaining the move. It also provides no broader market or sector catalyst; therefore, the weekly decline is best characterized as trading without an identified company-specific driver.
